

# Annual Report

## 2016



**hcoosier**<sup>SM</sup>  
CANCER RESEARCH NETWORK



# Board of Directors



## Officers

Christopher Fausel, PharmD — Chairman  
Bert O'Neil, MD — Chief Scientific Officer  
Annette Moore, MD — Secretary  
Charles Fox — Treasurer

## Members-At-Large

Sumeet Bhatia, MD  
Kerry Bridges, MBA, RN, CCRC  
Christopher LeMasters, MBA  
Ziyue Liu, PhD  
Patrick Loehrer, Sr., MD  
Timothy Ratliff, PhD  
Chris Wayne, MS, MBA, FACHE, CMPE  
Richard Zellars, MD

Hoosier Cancer Research Network's vision and mission is to form **unparalleled** relationships between academic, community, pharmaceutical, and biotech partners with the goal of **advancing** cancer research, education, and patient advocacy.

Our **highly qualified** team provides **comprehensive** study management and support, from conception and study design through project completion and publication.

# A message from our Chairman of the Board

Cancer is an unforgiving foe. Anyone who has endured treatment for their disease knows this all too well. As a pharmacist, I have the privilege of meeting countless women, men, and children who have begun the fight of their lives. These patients have taught me some very important lessons that impact my work every day. One of the greatest lessons is that success in the fight against cancer takes discipline and endurance.

It is a privilege for me to serve as chairman of Hoosier Cancer Research Network, and to personally witness the vital work of the staff in all areas of responsibility. Through their efforts, we are making real, measurable progress against cancer.

I'd like to share some numbers that illustrate this progress. Each of these numbers is impressive in its own right. Together, they illustrate the power of a coordinated approach to combatting a foe that has baffled countless generations.

- 11 new member sites
- 40+ trials in development at the end of 2016
- 58% increase in accruals over 2015
- 100's of site trainings and initiations conducted
- 240+ site payments made
- 250+ work orders and contracts executed
- 25,000+ samples collected and tracked
- 50,000+ forms built, queried, and verified

Indeed, we are advancing, and we commit to endure until the war is finally won. We owe a debt of gratitude to all those who have joined us, from investigators to funders, from advocates to financial contributors. Your support is more crucial than ever.



**Christopher A. Fausel,  
PharmD, MHA, BCOP**

Clinical Manager, Oncology Pharmacy  
Indiana University School of Medicine

A message from our

# Chief Scientific Officer



## Bert H. O'Neil, MD

Cusick Professor of Oncology  
Director, Phase I & GI Oncology  
Indiana University School of Medicine

**A**s a mission-driven nonprofit clinical research organization, Hoosier Cancer Research Network is committed to developing and managing research studies that make a tangible difference for patients.

We are proud to work with leading academic researchers, both in the lab and in the clinic, and community sites across the country that share our commitment to answering some of the most crucial questions in cancer research today.

Consider immunotherapy, for example. As a gastrointestinal researcher, I know how critical it is to find more effective treatments for my patients, who still have so few options. Immunotherapy offers hope for cancer patients across a variety of cancer types, with some patients experiencing exceptional responses. Yet, there remains a wide gap between those who respond and those who do not respond. Who will benefit from immunotherapy remains an unanswered question in many cancers.

I am excited that HCRN is on the frontlines of addressing these questions. With more than 30 years of leadership in multi-site, investigator-initiated clinical research, HCRN is increasingly sought out to manage research studies that are beyond the capabilities of single institutions.

Our network of more than 150 clinical research sites, including more than 50 academic institutions, allows us to pre-identify the best-performing sites for each study. Our staff deftly manages each stage of clinical trial development and management, from LOI submission, review by Clinical Trial Working Groups, protocol development, custom EDC builds, project management, safety and monitoring, through data reporting and publication.


I am convinced there is no other organization that does this work as effectively as HCRN, and I look forward to continued progress in the coming year.

A handwritten signature in black ink, appearing to read "Bert O'Neil". The signature is fluid and cursive, written on a white background.

# Honoring Excellence

## Sandra Turner Excellence in Clinical Research Award

“**T**he best part of my job is seeing and speaking with my patients. I have probably been told I spend too much time with them. ... With research, sometimes it takes coming in early or staying late; Trying to get something done for a deadline, that is just a part of it. ... It’s the passion to be there with your patient and do what you can to help them live, to know that we are doing everything we can to fight their cancer, to help them on those down days, to help them look up and find hope in a new day, no matter what the outcome may be. ... As Hoosier Cancer Research Network works so hard to find clinical trials, I am the lucky one that gets to work with the patient and present it to them as a possibility.”




### 2016 Recipient Cara Ellis, RN, BSN

Clinical Research Coordinator,  
IU Health Central Indiana Cancer Centers

#### About the Award

The Sandra Turner Excellence in Clinical Research Award was established in 2002 by William B. Fisher, MD, through the George and Sarah Jane Fisher Fund to honor the memory of Sandra Turner, the first executive director of Hoosier Cancer Research Network. Recipients exemplify qualities which Sandra Turner possessed, such as sustained professional commitment, contribution to the progress of oncology care, and unflinching compassion.

# Honoring Excellence



## Sandra Turner Excellence in Clinical Research Award

“ I was really intrigued by the medical side of things, reading the reports. I’d always been a science-based person. There was a part of me that knew I needed to do something, and so I found it. ... I worked on the inpatient research unit at University Hospital on some of the groundbreaking work of Dr. Larry Einhorn; I got to take care of my own patients. That is where I first fell in love with research. ... I love research, and I love regulatory. I can really see the value. I try to apply it to my day-to-day patient care because ultimately, while we are giving them a novel treatment or a standard treatment in a different way, the research and the science behind it are important. ”



### 2016 Recipient

#### Stacey Richardson, RN, BSN

Clinical Research Coordinator,  
Community Health Network

#### Working with HCRN

From her station at Community Health Network, Richardson appreciates working with Hoosier Cancer Research Network. “Staff are just very, very friendly. I do not feel like I have to start here and then keep working my way up; I can call a project manager,” she said. “You do not feel like it is a corporate sponsorship or a big huge CRO. It’s been a really good experience.”

# Honoring Excellence

## George and Sarah Jane Fisher Young Investigator Award

“One of the things that fascinates me about oncology is the breadth of the questions; I derive the most joy when I am thinking about and trying to answer these questions. I would like a career where I can do some clinical work but also do laboratory investigations into some of the questions that I may have or that the community has in terms of managing cancers, particularly gastrointestinal cancers.”

### 2016 Recipient **Olumide Gbolahan, MD**

Hematology/Oncology Fellow,  
Indiana University School of Medicine



### About the Research

Working in Dr. Murray Korc's lab, Dr. Gbolahan is investigating targeted agents in the management of pancreatic cancer. "He has some very interesting animal models of the disease," Dr. Gbolahan said. "We are beginning to see some evidence that we may be able to manipulate the immune system, even in pancreatic cancer, which is considered to be resistant to the immune response to other cancers. I want to be able to combine standard treatment agents with something like immunotherapy.

### About the Award

In 2011, William B. Fisher, MD and others generously established a new award through the George and Sarah Jane Fisher Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Young Investigator Award honors Indiana University oncology fellows and faculty members who have made significant contributions to clinical or basic science research in collaboration with Hoosier Cancer Research Network.

# Honoring Excellence



## Danny Danielson Translational Innovation Award

“ I am opening two phase one studies in pancreatic cancer. There is a lot we need to learn about biomarkers in particular with the investigational agent that I am using, which is called CPI-613, as well as immunotherapy research. When immunotherapy works, it’s very exciting. However, not every patient responds and we also do not know enough about sequence with chemotherapy or other treatments. We don’t know enough about biomarkers. It is a very rich area of research. So I am planning to position this award towards a translational investigation in pancreatic cancer and immunotherapy. ”

### 2016 Recipient Angela Alistar, MD

Medical Director, GI Medical Oncology,  
Morristown Medical Center,  
Atlantic Health System Cancer Care



#### About the Award

The late Donald C. “Danny” Danielson established the Danny Danielson Translational Innovation Award in 2013, granted by the Walther Cancer Foundation. The award is given to investigators working in partnership with Hoosier Cancer Research Network to support the correlative components of clinical trial protocols when financial support is not otherwise available.




# Honoring Excellence

## Terry Hoepner Patient Advocacy Award

“ tell everyone where I work that the patients in the beds at the hospital take priority. They come here, and they want us to help them, and that is what we are supposed to do. So, when you walk in the door you have got to be on your game and pay attention; it is a very important job. ... There are a lot of different options to get things. You have to try and cover all the bases just to find out which avenue is going to get it first. ... I kind of like being behind the scenes. The patients do not really know from where all their stuff comes when it shows up, and that is okay. They do not have to know what measures we went through on the backside to get it there, just that they did not have any problems: they got it, they used it, and they are okay. I find that rewarding.

### 2015 Recipient Billye Lutane

Pharmacy Buyer, University Hospital,  
Riley Hospital, IU Simon Cancer Center



### About the Award

Terry Hoepner, beloved Indiana University football coach, lost his battle with brain cancer in 2007. Coach Hep was known for his “never quit” attitude and determination to face challenges head-on. To honor his memory, his wife, Jane Hoepner, created the Terry Hoepner Patient Advocacy Award. The award honors individuals who embody Coach Hep’s spirit and determination to champion their cause.

# Honoring Excellence



## Hoosier Cancer Research Network Lifetime Achievement Award

**W**illiam B. Fisher, MD, is one of six oncologists who founded Hoosier Cancer Research Network (known then as the Hoosier Oncology Group) in the mid 1980s, and served as its founding vice chair. Dr. Fisher has served as a medical oncologist for more than 40 years at IU Health Ball Memorial Cancer Center. He has remained a strong supporter of the vision for collaborative research to expand patient access to clinical trials throughout the state of Indiana and beyond. In honor of his longstanding commitment, HCRN presented Dr. Fisher with the organization's first-ever Lifetime Achievement Award in 2016.



### Celebrating a Life of Service

Family, friends, and colleagues joined Dr. Fisher during HCRN's annual holiday party in 2016 to honor his service over four decades.



# Publications & Abstracts

## QL12-153

**Authors:** Adra N, Albany C, Brames MJ, Case-Eads S, Johnson CS, Liu Z, Fausel CA, Breen T, Hanna NH, Hauke RJ, Picus J, Einhorn LH

**Phase II study of fosaprepitant+5HT3 receptor antagonist+dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.**

*Support Care Cancer. 2016 Jul;24(7):2837-42. doi: 10.1007/s00520-016-3100-y. Epub 2016 Feb 2.*

## GU10-148

**Authors:** Matt D. Galsky, Noah M. Hahn, Costantine Albany, Mark T. Fleming, Alexander Starodub, Przemyslaw Twardowski, Sumanta K. Pal, Ralph J. Hauke, Guru Sonpavde, William K. Oh, Nina Bhardwaj, Sacha Gnjatic, Seunghye Kim-Schulze, Ziyue Liu; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Johns Hopkins University School of Medicine, Baltimore, MD; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; US Oncology Research, Virginia Oncology Associates, Hampton, VA; Indiana University Health Goshen Center for Cancer Care, Goshen, IN; City of Hope, Duarte, CA; Nebraska Cancer Specialists, Omaha, NE; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; Division of Hematology/Medical Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Mount Sinai Medical Center, New York, NY; Icahn School of Medicine at Mount Sinai, New York, NY; Columbia Univ, New York, NY; Division of Biostatistics, Indiana University, Indianapolis, IN

**Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.**

*J Clin Oncol 34, 2016 (suppl 2S; abstr 357)*

## GU14-188

**Authors:** Christopher J. Hoimes, Robert Abouassaly, Joel N. Saltzman, Mark T. Fleming, Jean H. Hoffman-Censits, Tara Byrd, Cheryl Eitman, Michele Snyder-Willis, Jodi O'Neill, Lisa Wood, Robin Elliott, Matthew M. Cooney; Case Comprehensive Cancer Center at Seidman Cancer Center, Cleveland, OH; University Hospitals Case Medical Center, Cleveland, OH; University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH; US Oncology Research, Virginia Oncology Associates, Hampton, VA; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Seidman Cancer Center at Lake, Cleveland, OH; Hoosier Cancer Research Network, Indianapolis, IN; Dept of Pathology, UH-Case Medical Center, Cleveland, OH; University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

**HCRN GU14-188: neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC).**

*J Clin Oncol 34, 2016 (suppl; abstr TPS4578)*

## GU12-157

**Authors:** Noah M. Hahn, Trinity J. Bivalacqua, Ashley Ross, George J. Netto, Jong Chul Park, Timothy A. Masterson, Michael O. Koch, Richard Bihle, Richard Foster, Thomas A. Gardner, Liang Cheng, David R Jones, Kyle McElyea, George Sandusky, Ziyue Liu, Scott A Turner, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, Daniel M. Geynisman; Johns Hopkins Kimmel Cancer Center, Baltimore, MD; The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD; Johns Hopkins University School of Medicine, Baltimore, MD; The Johns Hopkins Medical Institutions, Baltimore, MD; Indiana University School of Medicine, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN; Division of Biostatistics, Indiana University, Indianapolis, IN; Dartmouth Giesel School of Medicine, Lebanon, NH; The Geisel School of Medicine at Dartmouth and Dartmouth Hitchcock Medical Center, Lebanon, NH; Fox Chase Cancer Center, Philadelphia, PA

**Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.**

*J Clin Oncol 34, 2016 (suppl; abstr 4526)*

## GU14-202

**Authors:** John Paul Flores, Paul Mathew; Tufts Medical Center, Boston, MA

**Combination therapy with enzalutamide and the poly (ADP-ribose) polymerase-1 (PARP1) inhibitor niraparib in castration-resistant prostate cancer (CRPC): HCRN GU 14-202.**

*J Clin Oncol 34, 2016 (suppl; abstr TPS5095)*

## LUN14-179

**Authors:** Greg Andrew Durm, Ebenezer A. Kio, William B. Fisher, Michael L. Titzer, Salma Jabbour, TIM Breen, Ziyue Liu, Nasser H. Hanna; Indiana University Simon Cancer Center, Indianapolis, IN; Goshen Center for Cancer Care, Goshen, IN; Indiana University Health Ball Memorial Hospital, Muncie, IN; Oncology Hematology Associates of Southwest Indiana, Newburgh, IN; Cancer Inst of New Jersey Robert Wood Johnson Univ Hosp, New Brunswick, NJ; Hoosier Cancer Research Network, Indianapolis, IN; Division of Biostatistics, Indiana University, Indianapolis, IN; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN

**Phase II trial of consolidation Pembrolizumab following concurrent chemoradiation in patients (pts) with unresectable or inoperable stage III non-small cell lung cancer (NSCLC): initial safety data from HCRN LUN 14-179.**

*J Clin Oncol 34, 2016 (suppl; abstr e20025)*

See all HCRN publications at:

[hoosiercancer.org/category/publications/](https://www.hoosiercancer.org/category/publications/)

# Our Member Network

## Alabama

- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

## Arizona

- Mayo Clinic, Phoenix
- University of Arizona Cancer Center at Dignity Health St. Joseph's, Phoenix
- Yuma Regional Cancer Center, LLC, Yuma

## Arkansas

- Genesis Cancer Center, Hot Springs

## California

- Cedars-Sinai Medical Center, Los Angeles
- City of Hope, Duarte
- Marin Specialty Care, Greenbrae
- Moore's Cancer Center at UC San Diego Health, San Diego
- Prostate Oncology Specialists, Inc., Marina Del Rey
- University of California Los Angeles (TRIO), Pasadena
- USC Norris Comprehensive Cancer Center, Los Angeles

## Colorado

- University of Colorado Cancer Center, Aurora

## Florida

- Memorial Breast Cancer Center at Memorial Regional Hospital, Hollywood
- UF Health Cancer Center at Orlando Health, Orlando
- Moffitt Cancer Center, Tampa
- University of Florida Health Cancer Center, Gainesville
- University of Miami, Miami

## Georgia

- Winship Cancer Institute of Emory University, Atlanta

## Illinois

- Illinois CancerCare, PC, Galesburg
- Oncology Specialists, S.C., Niles
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- Rush University Medical Center, Chicago
- University of Chicago Medical Center, Chicago
- University of Illinois Cancer Center, Chicago

## Indiana

- Community Healthcare - Primary Care Oncology, Munster
- Community Hospital of Anderson and Madison County, Inc., Anderson
- Community Regional Cancer Centers, Indianapolis
- Floyd Memorial Cancer Center of Indiana, New Albany
- Fort Wayne Medical Oncology & Hematology, Fort Wayne
- Good Samaritan Hospital, Vincennes
- Goshen Center for Cancer Care, Goshen
- Hope Center, Terre Haute
- Horizon Oncology Research, Inc., Lafayette
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Arnett Cancer Centers, Lafayette
- IU Health Ball Memorial Hospital Cancer Center, Muncie
- IU Health Cancer Centers Bloomington, Bloomington
- IU Health Central Indiana Cancer Centers, Indianapolis
- Jasper Memorial Hospital, Jasper
- Kosciusko Community Hospital Cancer Care Center, Warsaw
- Oncology Hematology Associates of SW Indiana, Newburgh
- Radiation Oncology Associates, Fort Wayne
- St. Vincent Anderson Regional Hospital, Anderson
- St. Vincent Health, Indianapolis
- Union Hospital, Inc., Terre Haute

## Iowa

- Holden Comprehensive Cancer Center, University of Iowa, Iowa City

## Kansas

- Cancer Center of Kansas, Wichita

## Kentucky

- University of Louisville, Louisville

## Louisiana

- LSU Health Care Center, Houma
- Ochsner Clinic Foundation, New Orleans

## Maryland

- Merit Center for Clinical Research / John R. Marsh Cancer Center, Hagerstown
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- University of Maryland Greenebaum Cancer Center, Baltimore

## Massachusetts

- Dana-Farber Cancer Institute, Boston
- Tufts Medical Center, Boston

## Michigan

- Barbara Ann Karmanos Cancer Center, Detroit
- The Cancer Center at Metro Health Village, Wyoming
- Henry Ford Health System, Detroit
- Michigan Center of Medical Research, Farmington Hills
- University of Michigan Comprehensive Cancer Center, Ann Arbor

## Minnesota

- HealthPartners Institute, Minneapolis
- Masonic Cancer Center, University of Minnesota, Minneapolis

## Missouri

- Washington University School of Medicine / Siteman Cancer Center, St. Louis

## Nebraska

- GU Research Network, LLC, Omaha
- Nebraska Cancer Specialists, Omaha
- Nebraska Methodist Hospital, Omaha

## New Hampshire

- Dartmouth-Hitchcock Norris Cotton Cancer Center, Lebanon

## New Jersey

- Atlantic Health System, Morristown
- John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
- Regional Cancer Care Associates, LLC, Cherry Hill
- Rutgers Cancer Institute of New Jersey, New Brunswick
- Virtua Fox Chase Cancer Program, Mt. Holly


## New Mexico

- University of New Mexico Cancer Center (NMCCA), Albuquerque

## New York

- Columbia University Medical Center, New York
- Integrated Medical Professionals, PLLC, Melville
- Tisch Cancer Institute at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
- New York University Cancer Institute, New York
- Roswell Park Cancer Institute, Buffalo
- University of Rochester Medical Center, Rochester

# Our Member Network



Learn more at:  
[hoosiercancer.org/  
our-network/](https://hoosiercancer.org/our-network/)

## North Carolina

-  Comprehensive Cancer Center of Wake Forest University, Winston-Salem
-  Novant Health Oncology Specialists, Winston-Salem
-  University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill

## Ohio

-  Cleveland Clinic Taussig Cancer Institute, Cleveland
-  The Ohio State University, Columbus
-  University of Cincinnati Cancer Institute, Cincinnati
-  University Hospitals Seidman Cancer Center, Cleveland

## Oklahoma

Mercy Clinic Oncology and Hematology - McAuley, Oklahoma City

## Oregon

-  Oregon Health & Sciences University, Portland
-  Providence Cancer Center, Portland

## Pennsylvania

-  Allegheny General Hospital, Pittsburgh
-  Fox Chase Cancer Center, Philadelphia
-  Gettysburg Cancer Center, Gettysburg
-  PinnacleHealth Cancer Care, Harrisburg
-  Thomas Jefferson University / Sidney Kimmel Cancer Center, Philadelphia
-  University of Pennsylvania, Philadelphia

## South Carolina

-  Medical University of South Carolina / Hollings Cancer Center, Charleston

## Tennessee

-  Erlanger Health System, Chattanooga
-  Vanderbilt-Ingram Cancer Center, Nashville
-  West Cancer Center, Memphis

## Texas

-  Baylor College of Medicine - Methodist Breast Center, Houston
-  Cancer Therapy & Research Center at UT Health Science Center, San Antonio
-  Joe Arrington Cancer Research and Treatment Center, Lubbock
-  MD Anderson Cancer Center, Houston
-  Medicus Alliance Clinical Research, Houston
-  Texas Oncology PA, Dallas
-  UT Medical Branch at Galveston, Galveston
-  UT Southwestern Medical Center, Dallas

## Utah

-  Huntsman Cancer Institute at Univ. of Utah, Salt Lake City

## Virginia

-  University of Virginia Cancer Center, Charlottesville
-  Virginia Oncology Associates, Norfolk

## Washington

-  University of Washington, Seattle

## Washington, D.C.

-  George Washington University Cancer Center
-  Georgetown University Medical Center

## Wisconsin

-  Aurora Research Institute, LLC, Milwaukee
-  Clement J. Zablocki VA Medical Center, Milwaukee
-  Froedtert & the Medical College of Wisconsin, Milwaukee
-  University of Wisconsin Carbone Cancer Center, Madison

## Canada


-  Cancer Care Manitoba, Winnipeg
-  Centre Hospitalier de l'Université de Montréal, Montréal
-  Cross Cancer Institute, Edmonton
-  Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
-  Tom Baker Cancer Centre, Calgary
-  Vancouver Centre - BC Cancer Agency, Vancouver

# Partners in Research

## Courage to Climb

Columbus North High School (Columbus, IN)

When Columbus North High School choir director Janie Gordon was diagnosed with breast cancer in 2009, her students secretly planned a benefit concert in her honor, naming it Courage to Climb. The concert became an annual event. Since 2011, Columbus North High School students have organized this inspiring annual event, with donations to HCRN exceeding \$27,000. These gifts strengthen our ability to provide funding for innovative research in a variety of cancer types, leading to improvements in care and treatment options that are tailored to each patient's unique characteristics.



*Pictured: Janie Gordon with Courage to Climb 2016 student coordinators Sarah Pankratz and Caleb Bray.*



## Reps for Research

HCRN Chairman Chris Fausel has once again raised the bar in the fight against cancer. In spring 2016, he reissued his unique challenge to friends and supporters of HCRN: the Reps for Research challenge. Combining his interest in strength training and his passion for investigator-initiated research, Fausel invited pledges for every bench-press “rep” he could complete at the Arnold Sports Festival’s 5K Pump and Run event in Columbus, Ohio. In its first two years, Reps for Research raised nearly \$5,000 in donations to HCRN.

# Our Contributors

**T**hank you to all who have contributed to Hoosier Cancer Research Network. We are grateful for your commitment of time and resources to help us fulfill our mission. Your generous support strengthens our ability to fund investigator-initiated research. Learn how YOU can contribute to cancer research at [www.hoosiercancer.org/make-a-difference/](http://www.hoosiercancer.org/make-a-difference/).

## Contributions Received in 2016

Rafat Abonour  
JoLynn Bahr — *in memory of Donald Bahr*  
Brent Barta  
John Baute  
Alecia Burkhardt  
Cynthia Burkhardt — *in memory of John Waffle*  
Meg Connolly — *in memory of Clyde Wheeler*  
Clack Corporation — *in memory of Diana L. Flower*  
Columbus North High School — *in honor of Janie Gordon*  
Julie and Michael Current — *in memory of Sarah Jane Fisher*  
Randal Dillinger — *in honor of Ila VanderKolk*  
Christopher Fausel — *in memory of Gerald Fausel*  
David Fisher — *in memory of Sarah Jane and George Fisher;*  
*in honor of William B. Fisher*  
John Fisher — *in memory of Sarah Jane and George Fisher*  
Kevin and Becca Fisher — *in memory of Sarah Jane and George Fisher;*  
*in honor of William B. Fisher*  
William Fisher — *in memory of Sarah Jane and George Fisher*  
Sara Grethlein — *in honor of Chris Fausel*  
Pamela Griffin — *in memory of Carolee Ford*  
Nasser Hanna  
HCRN Staff — *in honor of Georgia Gould*  
Chris LeMasters  
Cindy and Chris Lynn — *in memory of Sarah Jane and George Fisher;*  
*in honor of William B. Fisher*  
Kirsten Malacina  
Cara Martin — *in memory of Skip Herring*  
Rakesh Mehta  
Annette Moore  
John D. Nell  
Megan Reimann  
Jessica Roy  
Daniel Rushing  
Safi Shahda  
C. Thomas Sibert — *in honor of Andrew Greenspan, MD*  
Robert Stresino  
Donna Sullivan  
Lisa Wood — *in memory of Gerald Fausel*

Did you know you can support HCRN through purchases made through Amazon Smile? When you shop, Amazon will donate a portion of your purchase cost to HCRN. Scan the code below or visit <https://smile.amazon.com/ch/26-0303542> to get started!



# hoosier<sup>SM</sup>

CANCER RESEARCH NETWORK



\$64 ea. + NON-REP PLEDGES  
\$ 1,920 + \$ 985 = \$ 2,905